AVTE Aerovate Therapeutics Inc
Price (delayed)
$2.52
Market cap
$73.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.44
Enterprise value
$39.71M
Highlights
The quick ratio has soared by 196% YoY and by 139% from the previous quarter
AVTE's debt is down by 38% YoY and by 23% from the previous quarter
The company's equity fell by 30% YoY and by 5% QoQ
Key stats
What are the main financial stats of AVTE
Market
Valuations
Earnings
Shares outstanding
28.99M
Market cap
$73.04M
Enterprise value
$39.71M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.95
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$74.6M
Net income
-$69.63M
EBIT
-$69.57M
EBITDA
-$69.29M
Free cash flow
-$71.2M
Per share
Balance sheet
Liquidity
EPS
-$2.44
EPS diluted
-$2.44
Free cash flow per share
-$2.49
Book value per share
$2.65
Revenue per share
$0
TBVPS
$2.81
Total assets
$80.33M
Total liabilities
$3.9M
Debt
$417,000
Equity
$76.43M
Working capital
$76.29M
Debt to equity
0.01
Current ratio
20.93
Quick ratio
20.54
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-71.4%
Return on equity
-81.4%
Return on invested capital
-115.7%
Return on capital employed
-90.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVTE stock price
How has the Aerovate Therapeutics stock price performed over time
Intraday
0.4%
1 week
0.4%
1 month
3.7%
1 year
-91.48%
YTD
-4.91%
QTD
0.4%
Financial performance
How have Aerovate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$74.6M
Net income
-$69.63M
Gross margin
N/A
Net margin
N/A
The net income rose by 18% since the previous quarter and by 8% year-on-year
AVTE's operating income is up by 17% since the previous quarter and by 8% year-on-year
Growth
What is Aerovate Therapeutics's growth rate over time
Valuation
What is Aerovate Therapeutics stock price valuation
P/E
N/A
P/B
0.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AVTE's EPS is up by 18% since the previous quarter and by 15% year-on-year
The price to book (P/B) is 66% less than the last 4 quarters average of 2.8
The company's equity fell by 30% YoY and by 5% QoQ
Efficiency
How efficient is Aerovate Therapeutics business performance
The company's return on invested capital fell by 35% YoY but it rose by 2.8% QoQ
The return on equity has declined by 32% year-on-year but it has increased by 10% since the previous quarter
The return on assets has declined by 30% year-on-year but it is up by 8% since the previous quarter
Dividends
What is AVTE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVTE.
Financial health
How did Aerovate Therapeutics financials performed over time
Aerovate Therapeutics's current ratio has soared by 197% YoY and by 138% from the previous quarter
The quick ratio has soared by 196% YoY and by 139% from the previous quarter
AVTE's debt is 99% less than its equity
AVTE's debt is down by 38% YoY and by 23% from the previous quarter
The company's equity fell by 30% YoY and by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.